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Abstract
The enzyme 5a-reductase, which converts testosterone to dihydrotestosterone (DHT), performs key functions in the
androgen receptor (AR) signaling pathway. The three isoenzymes of 5a-reductase identified to date are encoded by
different genes: SRD5A1, SRD5A2, and SRD5A3. In this study, we investigated mechanisms underlying androgen regulation of
5a-reductase isoenzyme expression in human prostate cells. We found that androgen regulates the mRNA level of 5a-
reductase isoenzymes in a cell type–specific manner, that such regulation occurs at the transcriptional level, and that AR is
necessary for this regulation. In addition, our results suggest that AR is recruited to a negative androgen response element
(nARE) on the promoter of SRD5A3 in vivo and directly binds to the nARE in vitro. The different expression levels of 5a-
reductase isoenzymes may confer response or resistance to 5a-reductase inhibitors and thus may have importance in
prostate cancer prevention.
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Introduction
The multiyear, multistep process of prostate carcinogenesis and
its long latency period make prostate cancer ideal for chemopre-
vention [1]. The androgen receptor (AR) signaling pathway, which
is essential for prostate development and normal function, is also
central to prostate cancer’s pathogenesis and progression [2,3].
The key enzyme in AR signaling, 5a-reductase, converts
testosterone to the more potent androgen dihydrotestosterone
(DHT) [4]. Although testosterone can bind to and activate the AR,
DHT binds to it with a dissociation rate three times slower than
that of testosterone [5,6].
Three isoenzymes of 5a-reductase, which are encoded by
different genes (SRD5A1, SRD5A2, and SRD5A3), have been
identified. Immunohistochemical and polymerase chain reaction
(PCR) analyses of human prostate tissues suggest that SRD5A1
and SRD5A2 levels change with prostate cancer development and
progression [7,8,9]. In vitro studies have confirmed the 5a-
reductase activity of the more-recently identified SRD5A3 [10],
which was overexpressed in hormone-refractory prostate cancer
tissues [10,11]. Knockdown of SRD5A3 expression also reduced
the growth and viability of prostate cancer cells [10]. By using a
monoclonal antibody, Godoy et al. further showed increased level
of SRD5A3 protein in the prostate cancer compared to benign
prostate tissues [12]. These findings suggested that SRD5A3 may
contribute to prostate cancer progression. It has also been recently
reported that SRD5A3 may play an important role in protein
glycosylation [13]. Mutations of SRD5A3 result in congenital
disorders [13,14] and Kahrizi syndrome [15].
Two 5a-reductase inhibitors have been tested clinically.
Finasteride specifically inhibits SRD5A2 activity [16], and
dutasteride inhibits that of both SRD5A1 and SRD5A2 [17].
The Prostate Cancer Prevention Trial (PCPT) yielded encourag-
ing results: finasteride reduced the overall incidence of prostate
cancer by 25%, although potential effects of high-grade tumors
were concerning [18]. Similarly, the Reduction by Dutasteride of
Prostate Cancer Events (REDUCE) trial showed that dutasteride
reduced the incidence of prostate cancer by 23% among men at
high risk and revealed no statistically significant increase of high-
grade tumor in dutasteride-treated men [19,20].
Three factors may confer response or resistance to 5a-reductase
inhibitors. First, response or resistance may result from the
presence of different isoenzymes [21]. Second, differences in
sensitivity may be conferred by SRD5A2 genotypic variants [22];
Makridakis et al. [23] showed in vitro that SRD5A2 variants have
different affinities for finasteride. Third, different expression levels
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and resistance. Unlike androgen ablation, which decreases
prostatic testosterone and DHT, inhibition of 5a-reductase activity
decreases DHT but increases testosterone [24,25,26]. Since 5a-
reductase inhibitors change the testosterone-to-DHT ratio, and
given the critical role of 5a-reductase in AR signaling, the different
5a-reductase expression levels may provide clues about response
and resistance to 5a-reductase inhibitors in prostate cancer
prevention.
Androgens can affect the expression of SRD5A1 and SRD5A2 in
different tissues and cell types. In the rat ventral prostate, positive
regulation of SRD5A2 by androgen has been reported [27], and in
the rat testis, negative regulation of SRD5A1 [28]. Androgen
ablation led to decreased immunostaining of 5a-reductase [29].
SRD5A1 and SRD5A2 are also regulated by testosterone and DHT
in T and B lymphoid cells [30] and in rat liver and brain
[31,32,33,34]. However, how 5a-reductase expression is regulated
in human prostate cells has not been extensively investigated.
Our primary purpose of this study was thus to evaluate
androgen regulation of the 5a-reductase isoenzymes in human
prostate cells. We further investigated whether the regulatory
effects of androgens on the 5a-reductases are mediated by AR and
whether a direct interaction exists between the cis-regulatory
elements of 5a-reductase isoenzymes and AR.
Our data demonstrated cell type–specific androgen regulation
of the isoenzymes that is mediated by AR. To our knowledge, this
is the first demonstration that AR can directly bind to the negative
androgen response element (nARE) of the SRD5A3 promoter in
LNCaP prostate cancer cells. Our findings may have clinical
implications for identifying men whose disease may benefit from
5a-reductase inhibitors.
Materials and Methods
Cell lines and cultures
PWR-1E, LNCaP, and VCaP cells were obtained from the
American Type Culture Collection (ATCC, Manassas, VA); BPH-
1-GFP, BPH-1-AR, and C4-2B4 cells were a gift from Dr. Sue-
Hwa Lin (The University of Texas MD Anderson Cancer Center,
Houston, TX); and LAPC-4 cells were kindly provided by Dr.
Robert Reiter (University of California, Los Angeles, CA).
PWR-1E cells were maintained in serum-free keratinocyte
medium (Invitrogen, Life Technologies Corp., Carlsbad, CA)
supplemented with 50 mg/mL bovine pituitary extract, 5% L-
glutamine, and 5 ng/mL epidermal growth factor. LNCaP, C4-
2B4, BPH-1-GFP, and BPH-1-AR cells were maintained in
RPMI-1640 medium with 10% fetal bovine serum (FBS) and 1%
penicillin and streptomycin (P/S). LAPC-4 cells were maintained
in Iscove’s modified Dulbecco’s medium (Invitrogen) supplement-
ed with 5% FBS and 1% P/S. VCaP cells were maintained in
Dulbecco’s Modified Eagle’s Medium supplemented with 10%
FBS and 1% P/S. All cultures were maintained at 37uCi n
humidified air with 5% CO2. Cell lines were validated at MD
Anderson’s Characterized Cell Line Core by STR DNA
fingerprinting using the AmpF,STR Identifiler kit (Applied
Biosystems, Life Technologies Corp., Carlsbad, CA). The STR
profiles were compared to the known ATCC fingerprints, to the
Cell Line Integrated Molecular Authentication Database version
0.1.200808 (http://bioinformatics.istge.it/clima/) [35], and to
MD Anderson’s fingerprint database. The STR profiles of
PWR-1E, LNCaP, C4-2B4, and VCaP cells matched known
DNA fingerprints; those of BPH-1-AR and LAPC-4 cells were
unique.
Quantitative reverse-transcription PCR (qRT-PCR)
Total RNA was extracted from each cell line by using an
RNeasy Plus mini kit (Qiagen Inc., Valencia, CA) according to the
manufacturer’s protocol. qRT-PCR was performed by using a
TaqMan One-Step RT-PCR kit (Applied Biosystems, Life
Technologies Corp.), according to the manufacturer’s instructions.
Briefly, the qRT-PCR setting for each reaction was 48uC for
30 minutes, 95uC for 10 minutes, and 42 cycles of 95uC for
15 seconds and 60uC for 1 minute. Human b-actin was used as
the endogenous control in each reaction. Primer and probes for
SRD5A1, SRD5A2, and SRD5A3 genes were also from Applied
Biosystems.
Androgen treatment
Testosterone and DHT were purchased from Sigma-Aldrich
(St. Louis, MO). R1881, a synthetic androgen, was kindly
provided by Dr. Sue-Hwa Lin. Cells were seeded in 12-well
plates with their regular growth medium. After serum starvation
overnight, cells were exposed to ethanol (control) or to 1 nM,
10 nM, or 100 nM androgen. After 24-hour and 48-hour
incubation, cells were harvested and RNA extracted for qRT-
PCR analysis.
Actinomycin D treatment
BPH-1-AR, LNCaP, and PWR-1E cells were treated with
dimethyl sulfoxide (DMSO; control) or 1 mg/mL or 5 mg/mL of
actinomycin D for 30 minutes, followed by ethanol (control) or
10 nM DHT. After 24 hours’ incubation, cells were harvested and
total RNA extracted.
Transfection with small interfering RNA (siRNA)
To knock down AR expression, we seeded LNCaP cells in 12-
well plates, serum starved them overnight, and then transfected
them with 20 nM AR siRNA or control siRNA by using
DharmaFECT 1 (Dhamarcon, Inc., Thermo Fisher Scientific,
Lafayette, CO). After incubation overnight, cells were exposed to
ethanol (control) or 2 nM DHT. The AR siRNA and control
siRNA were obtained from Dhamarcon.
Western blot analysis
After 24 hours of incubation with siRNA, the cells were
harvested and centrifuged at 5,000 rpm for 5 minutes. Cell pellets
were resuspended in RIPA buffer (Boston Bioproducts, Inc.,
Ashland, MA) with protease inhibitor (Roche, Mannheim,
Germany), incubated for 20 minutes with occasional vortex
mixing, and then centrifuged at 14,000 rpm for 10 minutes. The
supernatant was decanted and saved for Western blotting. The
whole protein-extraction procedure was performed at 4uC, and
the protein concentration was measured by using the BCA assay
(Thermo Fisher Scientific, Inc., Waltham, MA). The supernatant
was boiled for 5 minutes, loaded onto polyacrylamide gel, run,
and transferred to a PVDF membrane, which was then blocked in
TBST (TBS with 0.2% Tween 20) + 5% milk for 1 hour before
being probed with anti-AR antibody (Dako North America, Inc.,
Carpinteria, CA) in blocking buffer overnight at 4uC, followed by
incubation at room temperature for 1 hour with secondary
horseradish peroxidase–conjugated anti-mouse antibody. Detec-
tion was performed by using an electrochemiluminescence kit
(Amersham, GE Healthcare Bio-Sciences Corp., Piscataway, NJ).
Luciferase assay
The SRD5A3 promoter (21027/+155 bp) was cloned into the
pGL2 basic vector (Promega Corp., Madison, WI) at the XhoI
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were transfected with these constructs by using Fugene 6 reagent
(Roche) or Lipofectamine 2000 (Invitrogen).
To test the AR-dependent repression ability of SRD5A3, we
also inserted its promoter (2191/272 bp) into the pGL3–4ARE–
E4–luc construct at the PstI and XhoI sites. LNCaP cells were
transfected with it and then grown in the absence and presence of
DHT for 24 hours.
A dual-luciferase assay was conducted according to Promega’s
protocol. The luciferase ratio was derived by dividing the
luciferase activity by the Renilla activity.
Mutagenesis
Mutations were made in the nARE region of the SRD5A3
promoter by using a QuickChange II XL site-directed mutagenesis
kit (Strategene, Agilent Technologies, Inc., Santa Clara, CA)
according to the manufacturer’s instructions. The sequence
CTGTTTTGCGTCT was mutated to ATTTTTTTATTAT in
the context of the pGL3–4ARE–E4–luc construct.
Electrophoretic mobility-shift assay (EMSA)
AR’s binding to double-stranded oligos was assessed in LNCaP
cell nuclear extracts by performing EMSA with a LightShift kit (all
kits for EMSA were from Thermo Scientific) according to the
manufacturer’s instructions. Nuclear protein extracts were isolated
from LNCaP cells, and protein concentrations were determined by
using a BCA protein assay kit. Oligos were designed to cover the
2191/291 region on the SRD5A3 promoter and labeled by using
a biotin 39-end DNA labeling kit according to the manufacturer’s
instructions. AR binding to double-stranded oligos was assessed in
LNCaP cell nuclear extracts by EMSA using a LightShift kit
according to the manufacturer’s instructions. Unlabeled oligos
were used in EMSA as one of the controls. Biotin-labeled DNA
was detected on the nylon membrane by using a chemiluminescent
nucleic acid detection module kit.
Chromatin immunoprecipitation (ChIP) assay
LNCaP cells were cultured in both the presence and absence of
100 nM DHT, and ChIP was performed by using a kit from Cell
Signaling Technology, Inc. (Danvers, MA), according to their
protocol. Briefly, cells were treated with 37% formaldehyde to
cross-link proteins to DNA. Cross-linked chromatin was digested
by micrococcal nuclease to a length of 150–900 bp, and the
nuclear membranes were broken by sonication. AR-specific
antibodies (Dako) were used to precipitate the short chromatin
fragments, which were then washed and eluted. The protein–DNA
cross-links were reversed and DNA further purified by using spin
columns in each PCR reaction. The forward primer for the nARE
was CTGTTTTGCGTCTTTGCTTCTG, and the reverse
primer was GAGGTCCTTGGTCCTGGTC, which amplify a
120-bp product.
Xenograft models
RNA from the MDA PCa 183, MDA PCa 144, MDA PCa 146,
and MDA PCa 155 xenograft models was kindly provided by Dr.
Sankar N. Maity and Dr. Nora M. Navone. The MDA PCa 183
xenograft was derived from androgen-dependent prostate carci-
noma, whereas the others were derived from AR-negative
castrate-resistant prostate carcinomas with small-cell prostate
carcinoma (SCPC) morphology.
Quantification of the relative mRNA level of xenograft SRD5A3
and prostate-specific antigen (PSA) was done by using qRT-PCR
with SYBR Green (Applied Biosystems, Inc.). qRT-PCR was
performed as described in [36]. The primer sequences used were
as follows: SRD5A3: forward, 59-TCCAAGCTGGCTT-
CATGGTT-39 located on exon 2 and reverse, 59-CACTCGAA-
GAGTCTTCGTAA-39 located on exon 3; PSA: forward,
59-GAGAGCTGTGTCACCATGTG-39 located on exon 1
and reverse, 59-CACAATCCGAGACAGGATGA-39 located on
exon 2.
Statistical analysis
Data are presented as means 6 SD. Two-sided t tests were
conducted for comparing means between androgen-treated
samples and controls. Significance was set at a p value of 0.05.
Results
All three 5a-reductase isoenzymes are present in the
tested human prostate cell lines, with varying expression
patterns
To identify good model systems for studying the functions of 5a-
reductase isoenzymes, we evaluated the mRNA levels of the 5a-
reductase isoenzymes in different prostate cell lines, including
PWR-1E immortalized normal prostatic epithelial cells; BPH-1-
AR benign prostatic hyperplasia (BPH) cells, which stably express
AR; LAPC-4 and LNCaP androgen-sensitive prostate cancer cells;
and C4-2B4 androgen-independent cells. PWR1-E, BPH-1-AR
and LAPC-4 cells express wild-type AR, whereas LNCaP and C4-
2B4 cells express a mutant AR, T877A. (The characteristics of
these cell lines, including their source, androgen sensitivity, and
AR-expression status, are summarized in Table S1.) As Figure 1
illustrates, the mRNA of all three 5a-reductase isoenzymes was
detected on qRT-PCR analysis of each cell line, indicating that all
three are expressed in these cell lines. However, the mRNA level
of each isoenzyme differed between cell lines, and each isoenzyme
had a distinctive expression pattern.
5a-Reductase mRNA levels are regulated by androgens in
a cell type–specific manner
To test whether the mRNA level of 5a-reductase is regulated by
androgens, we treated LNCaP cells with either ethanol (i.e.,
vehicle only) or with testosterone or DHT at different concentra-
tions (1, 10, and 100 nM). The normal plasma concentration of
testosterone in men ranges from 350 to 1050 ng/dL (12.1–
36.4 nM) [37], and the castrate level of testosterone is less than
50 ng/dL (1.73 nM) [38]. The plasma concentration of DHT is
about 1/10 of the testosterone concentration [39,40]. Thus, we
treated cells with concentrations of androgen that are close to the
castrate, physiologic, and superphysiologic levels. Our qRT-PCR
analysis showed that DHT treatment resulted in an increased level
of SRD5A1 mRNA, whereas it led to decreased levels of SRD5A2
and SRD5A3 mRNA in LNCaP prostate cancer cells (Fig. 2A).
We also tested the effect of DHT on other cell lines. DHT did
not notably affect the mRNA level of 5a-reductase in PWR-1E
cells (Fig. 2B), whereas in BPH-1-AR cells, DHT increased the
mRNA levels of all three isoenzymes (Fig. 2C). In LAPC-4 cells,
which express wild-type AR, DHT up-regulated SRD5A1
expression without affecting SRD5A2 and SRD5A3 expression
(Fig. 2D). And in the androgen-independent C4-2B4 prostate
cancer cells, DHT regulated 5a-reductase expression similarly to
its regulation in LNCaP cells, but to a lesser degree (Fig. 2E).
We found it interesting that DHT regulates the mRNA level of
SRD5A3 in a cell type–specific manner, a finding we have not seen
reported before. To evaluate whether this happens only in LNCaP
or LNCaP-derived cell lines, we similarly treated VCaP cells,
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prostate cancer. DHT also down-regulated the mRNA level of
SRD5A3 in VCaP cells (Figure S1), indicating that androgen-
negative regulation of SRD5A3 is not specific to LNCaP or
LNCaP-derived cell lines.
Testosterone and R1881 had effects similar to those of DHT on
the expression of 5a-reductase in all the cell lines tested (Figures S2
and S3). Our data thus demonstrate that androgens regulate the
mRNA level of 5a-reductase isoenzymes in a cell type–specific
manner.
Regulation of 5a-reductase mRNA level occurs through
transcription
Androgens could regulate 5a-reductase expression by control-
ling 5a-reductase transcription or by affecting mRNA stability. To
understand the mechanism underlying the regulation of 5a-
reductase by androgens, we treated BPH-1-AR cells with
actinomycin D, a transcription inhibitor. As shown by the results
of qRT-PCR analysis in Figure 3, DHT induced increased
expression of all three 5a-reductase isoenzymes relative to that in
the ethanol (vehicle) control in BPH-1-AR cells. However, the
mRNA level of 5a-reductase did not change with DHT treatment
when the cells were also treated with actinomycin D at 1 mg/mL
and 5 mg/mL concentrations (Fig. 3A). These results indicate that
the up-regulation of 5a-reductase expression by androgens is
sensitive to actinomycin D treatment, suggesting that androgens
regulate the transcription of 5a-reductase.
Similarly, when LNCaP cells were treated with actinomycin D,
testosterone did not significantly increase SRD5A1 or decrease
SRD5A2 and SRD5A3 mRNA levels (Fig. 3B). As a negative
control, we also treated PWR-1E cells with actinomycin D,
followed by DHT treatment (Fig. 3C). In the case of the DMSO-
only control, DHT did not affect the mRNA level of SRD5A1,
SRD5A2,o rSRD5A3. With actinomycin D treatment, DHT did
not significantly alter the mRNA level of these genes, either.
Regulation of 5a-reductase mRNA level by androgens is
AR dependent
By using Western blotting, we verified the expression of AR in
each of the studied cell lines by comparison with that of the AR-
negative BPH-1-GFP cells (Fig. 4A).
To determine whether AR is required to mediate regulation of
5a-reductase expression by androgens, we performed Western
blotting and qRT-PCR analysis after treating LNCaP and PWR-
1E cells with AR siRNAs and then with 2 nM DHT. Western
blotting and qRT-PCR validated the effective knockdown of AR
expression by the AR siRNAs (Fig. 4B). qRT-PCR showed that
the control siRNAs did not significantly alter the effect of DHT on
5a-reductase levels in LNCaP cells (Fig. 4C, top). DHT treatment
alone resulted in increased SRD5A1 mRNA but decreased SRD5A2
and SRD5A3 mRNA (Fig. 4C, top). In contrast, the 5a-reductase
levels in LNCaP cells treated with AR siRNAs did not change in
response to treatment with DHT (Fig. 4C, top). When we treated
LAPC-4 cells in a similar way, SRD5A1 mRNA similarly increased
with DHT or testosterone treatment alone, but not when cells
were also treated with AR siRNA (Figure S4). When we treated
PWR-1E cells in the same way, DHT did not affect the mRNA
level of 5a-reductase in PWR-1E cells, no matter whether they
were treated with control siRNAs or AR siRNAs (Fig. 4C,
bottom).
Taken together, these results indicate that the regulation of 5a-
reductase by androgens is AR dependent.
SRD5A3 promoter contains an nARE
We showed that androgen regulates the transcription of 5a-
reductase and that AR is necessary to mediate this transcriptional
regulation. AR directly binds to AREs and regulates the
transcription of the AR-targeted genes. Thus, we investigated
whether AR can directly regulate the transcription of 5a-
reductase. We cloned a promoter region of SRD5A3 (21027 to
+155 bp) into the pGL2-basic vector. In LNCaP cells, this
construct drives luciferase expression and, when they are treated
with 100 nM DHT, a 75% reduction of luciferase activity results
(Fig. 5A). This is similar to the response of endogenous SRD5A3 to
Figure 1. The expression pattern of 5a-reductase in prostate
cell lines varies. Graphs depict the relative mRNA levels of the
SRD5A1, SRD5A2, and SRD5A3 isoenzymes in PWR-1E, BPH-1-AR, LAPC-4,
LNCaP, and C4-2B4 cells as determined on qRT-PCR analysis.
doi:10.1371/journal.pone.0028840.g001
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28840Figure 2. DHT regulates the mRNA level of 5a-reductase differently in different prostate cell lines. A, LNCaP cells were treated with
ethanol (vehicle only) or different concentrations of DHT (1 nM, 10 nM, 100 nM) for 24 and 48 hours. PWR-1E (B), BPH-1-AR (C), LAPC-4 (D), and C4-
2B4 (E) cells were treated the same way but for only for 24 hours. The mRNA levels of SRD5A1, SRD5A2, and SRD5A3 for all cell lines were quantified by
qRT-PCR. *p,0.05, **p,0.01, ***p,0.001; 2-sided t test.
doi:10.1371/journal.pone.0028840.g002
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this 1-kb promoter region of SRD5A3.
To identify the putative ARE, we made a series of deletion
constructs in the SRD5A3 promoter region; the constructs retained
responsiveness to androgen treatment until the 2191/291 bps
were deleted, suggesting that the putative ARE is located in this
region (Fig. 5A).
To further evaluate whether this region indeed contains an
nARE, we inserted the region of 2191/272 bp between the
4ARE and E4 core promoter in the pGL3–4ARE–E4–luc
construct [41], transfected LNCaP cells with it, and then treated
the cells with DHT. The pGL3–4ARE–E4–luc construct contains
four tandem repeats of the ARE of the PSA gene and an E4 core
promoter [41]. As shown in Figure 5B, DHT treatment induced
about a 24-fold increase in luciferase activity of the pGL3–4ARE–
E4–luc construct. When the 2191/272-bp region of the SRD5A3
promoter was inserted between 4ARE and E4, luciferase activity
was increased only 3- to 6-fold by DHT treatment, suggesting that
this region contains an nARE. When a 101-bp region derived
from the SRD5A1 promoter (21601/21501 bp) was similarly
inserted between 4ARE and E4 as a control, DHT treatment still
induced a 26-fold increase in luciferase activity. Furthermore,
mutations in the 2191/272-bp region of SRD5A3 abolished its
repressive ability (Fig. 5C). Together, these data suggest that
SRD5A3 has a functional nARE in its promoter.
AR is recruited to the nARE-containing region of SRD5A3
To investigate whether AR is recruited to the promoter of
SRD5A3 in vivo, we performed ChIP using genomic DNA
fragments from LNCaP cells (150–900 bp; Fig. 6A) with primers
specifically targeting the nARE region of SRD5A3. As shown on
PCR, AR was enriched at the nARE region when cells grew in the
presence of DHT (Fig. 6B). Normal mouse immunoglobulin G (as
a negative control) was also used for immunoprecipitation with
LNCaP genomic DNA; the immunoglobulin G did not pull down
any AR-associated DNA sequences of the SRD5A3 promoter
(Fig. 6B). These results suggest that AR is recruited to the nARE
region in the promoter of SRD5A3.
Figure 3. Androgen regulation of 5a-reductase mRNA level is sensitive to actinomycin D treatment. BPH-1-AR (A) and LNCaP (B), and
PWR-1E (C) cells were treated for 30 minutes with DMSO (vehicle-only control) or actinomycin D at 1 mg/mL and 5 mg/mL concentrations. Treatment
with either ethanol (vehicle only) or 10 nM DHT or testosterone followed. We quantified the mRNA levels of SRD5A1, SRD5A2, and SRD5A3 by qRT-
PCR.
doi:10.1371/journal.pone.0028840.g003
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of SRD5A3, we carried out EMSA with three oligo probes, each of
40 bp, to cover the 2191/291-bp region of the SRD5A3
promoter (Fig. 6C). Only probe 1 showed a mobility shift
(Fig. 6D). To confirm that this mobility shift is specific to AR,
we added anti-AR antibodies to the reactions; probe 1 showed a
further mobility shift (Fig. 6D). Although unlabeled wild-type
probe 1 was able to compete with labeled probe 1 for AR binding
in EMSA, it lost that ability when we made mutations in the probe
1 sequence (Figure S5).
These results demonstrated that probe 1 contains the nARE and
that AR directly binds to this region in vitro.
For SRD5A1 and SRD5A2, we also conducted promoter analysis
and ChIP, but we did not detect an ARE region or direct AR
binding to their proximal promoter regions. The regulational
mechanism for their expression is still under investigation.
SRD5A3 mRNA increases in the AR-negative SCPC
xenograft model
On observing the androgen-negative regulation of SRD5A3 in
the tested cell lines, we were interested in investigating whether
this AR-dependent regulation also occurs in vivo. Therefore, we
examined the mRNA level of SRD5A3 in different xenograft
models, including MDA PCa 183, an AR-expressing androgen-
dependent prostate cancer xenograft, and three AR-negative
androgen-independent SCPC xenografts, MDA PCa 144, MDA
PCa 146, and MDA PCa 155. On qRT-PCR, we observed a
remarkably higher mRNA level of PSA in the MDA PCa 183
xenograft than in the others (Fig. 7, top), which is consistent with
the AR status of these cell lines. In contrast, the mRNA level of
SRD5A3 in the AR-positive xenograft MDA PCa 183 was much
lower than that in the AR-negative SCPC xenografts, except for
MDA PCa 155 (Fig. 7, bottom), suggesting a loss of AR-negative
regulation in the MDA PCa 144 and MDA PCa 146 xenografts.
This result is consistent with the mechanism underlying the
androgen-negative regulation of SRD5A3 expression that we found
in the prostate cancer cell lines.
Discussion
The results of this study show that androgens regulate the
expression of 5a-reductase isoenzymes in a cell type–specific
manner. They also show that androgens regulate the transcription
of 5a-reductase isoenzymes and that such regulation is mediated
by the AR. Furthermore, to our knowledge, this is the first
publication of evidence that SRD5A3 has at least one nARE and
that AR directly binds to this nARE region, demonstrating that
SRD5A3 is under transcription inhibition by AR in prostate cancer
cells. Altogether, our results elucidate a mechanism by which
androgens regulate the expression level of 5a-reductase isoen-
zymes; this may have clinical implications, by revealing a
mechanistic basis for the response and/or resistance to 5a-
reductase inhibitors.
In this study, the mRNA level of 5a-reductase did not fully
correlate with previously reported immunostaining results in
Figure 4. Regulation of 5a-reductase mRNA level by DHT is AR dependent. A, The AR protein level of each prostate cell line was analyzed by
Western blotting. BPH-1-GFP cells were used as a negative control for AR expression. B, The AR protein level was analyzed by Western blotting for
LNCaP cells (left) with three control and two AR siRNA treatments. The AR mRNA level was analyzed by qRT-PCR for PWR-1E cells (right), also with
three control and two AR siRNA treatments. C, LNCaP and PWR-1E cells were treated with control siRNAs and AR siRNAs and then treated with 2 nM
DHT. We measured the mRNA levels of SRD5A1, SRD5A2, and SRD5A3 by using qRT-PCR and normalized the values to b-actin. The changes in mRNA
levels with DHT treatment are shown relative to the levels in cells treated with vehicle only.
doi:10.1371/journal.pone.0028840.g004
Androgen Regulation of 5a-Reductase Isoenzymes
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28840human tissues [8], but it is possible that the mRNA level during
different stages of prostate cancer development and progression
does not fully correlate with the protein levels as measured by
immunostaining. Luo and colleagues [7] detected no significant
difference in the SRD5A1 mRNA level between tumor samples
and BPH or normal samples, although Thomas et al. [8] found
greater SRD5A1 immunostaining in tumor samples than they
found in BPH samples. It is also possible that the mRNA level of
5a-reductase in this study was modified because we used
immortalized cell lines. Additionally, it remains controversial
how the 5a-reductase level changes with prostate cancer
development and progression, as shown in a recent study by
Wako et al. [42]: using semiquantitative immunohistochemical
analysis, they found no significant change in SRD5A1 and
SRD5A2 levels between localized prostate cancer samples and
normal prostatic tissues.
This study evaluated multiple cell lines that may represent the
processes of prostate cancer initiation and progression. Although
these are immortalized cell lines, the results still shed light on how
androgen may modulate the mRNA level of 5a-reductase during
different stages of prostate cancer pathogenesis and progression. In
PWR-1E cells, for example, androgens did not have a significant
effect on 5a-reductase expression. However, in BPH-1-AR cells,
which represent the transition between normal and cancerous
prostate cells,testosterone could up-regulate the mRNA levels of all
three 5a-reductase isoenzymes, which would result in high
concentrations of DHT in these cells and further increase the
expression of these isoenzymes. Such a positive-feedback loop is
most likely to lead to constant activation of the AR, which at least
partially explains the epidemiologic observation that a high
concentration of testosterone level correlates with a high incidence
of prostate tumor [43]. In our experiments, the LAPC-4, LNCaP,
and C4-2B4 prostate cancer cell lines responded differently to
androgen treatment. They also have different androgen sensitivity
and AR status, which is an important implication that blocking
DHT production with either 5a-reductase inhibitor may not be
the gold-standard prevention strategy in every man because the
androgen sensitivity, AR status and other factors of each particular
prostate cancer may influence expression of 5a-reductase
isoenzymes in reponses to blocking of DHT production.
Several genes, including PSA, TGF-b1,a n dmaspin,r e p o r t e d l y
c o n t a i na nn A R Ei nt h e i rcis-regulatory elements [41,44,45]. The
nARE in the PSA gene overlaps with the NF-kBb i n d i n gs i t e ,a n dA R
competes with NF-kB binding, resulting in the negative regulation of
PSA [44]. A 250-bp nARE region has also been mapped to the
promoter of TGF-b1, although no direct binding of AR to this region
has been detected [41]. Further, the AR binds to the nARE of the
maspin promoter [45]. However, the nARE in the promoter of
SRD5A3 has no notable similarity to that in PSA, TGF-b1,o rmaspin.
Therefore, we believe that we have found a novel nARE and have
demonstrated the direct binding of the AR to this region.
The SRD5A3 mRNA level was not consistently significantly
affected by androgens in PWR-1E cells, was up-regulated in BPH-
1-AR cells, but was down-regulated in LNCaP cells. These results
Figure 5. The SRD5A3 promoter contains a functional nARE. A,
Deletion analysis of SRD5A3 promoter to narrow down the location of
the nARE-containing region. LNCaP cells were transfected with
luciferase constructs containing a deletion series of SRD5A3 promoter
and then treated with ethanol (vehicle only; 2DHT) or 100 nM DHT
(+DHT) for 24 hours. Cells were then harvested, and their lysates were
used for the luciferase assay. B, SRD5A3 has an nARE. LNCaP cells were
transfected with pGL3–4ARE–E4 constructs with and without insertion
of the SRD5A3 promoter (2191/272 bp) sequence in both orientations
or with insertion of an SRD5A1 promoter fragment (21601/21501 bp).
Cells were treated with ethanol (vehicle only) or 100 nM DHT for
24 hours and then harvested for the luciferase assay. C, Mutations in the
nARE abolished its suppressive effect. LNCaP cells were transfected with
pGL3–4ARE–E4 constructs with and without insertion of SRD5A3
promoter (2191/272 bp) or with insertion of the mutated SRD5A3
promoter (2191/272 bp) and then subjected to DHT treatment and
the luciferase assay.
doi:10.1371/journal.pone.0028840.g005
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prostate cancer pathogenesis and progression—a loss of positive
regulation and gain of negative regulation—which is consistent
with the report that a lower testosterone level was found among
prostate cancer patients with higher Gleason scores than that in
those with lower Gleason scores [46]. It is also consistent with the
observation that SRD5A3 is overexpressed in hormone-refractory
prostate cancers in which the androgen level is low [10,11]. Our
identification of an nARE in the promoter of SRD5A3 allows us to
further investigate the transition from positive to negative
regulation of SRD5A3 expression that occurs with prostate cancer
progression over time.
The results of our evaluation of xenograft models provide
additional supporting evidence of the androgen-negative regula-
tion of SRD5A3. Because we did not use castrate xenograft models
and thus could not directly compare the effect of androgen
withdrawal on the AR-positive and -negative cells in vivo, we did
observe SRD5A3 overexpression in the AR-negative prostate
carcinoma xenografts MDA PCa 144 and MDA PCa 146, which
is consistent with results from our cell line study and previously
reported work [10,11]. Although morphologically similar, the
original donor tumor and the MDA PCa 155 subline xenograft
have slight differences from the MDA PCa 144 and MDA PCa
146 xenografts in terms of molecular characterization (person al
communication with Dr. Sankar N. Maity; a separate manuscript
under review elsewhere). It is possible that such differences have an
effect on the expression of SRD5A3, resulting in the relatively low
level of SRD5A3 in MDA PCa 155.
In this study, we did not detect an ARE in the proximal
promoter of SRD5A1 and SRD5A2, either by promoter analysis or
Figure 6. AR directly interacts with the nARE of the SRD5A3 gene. A, Agarose gel electrophoresis of the digested chromatin of LNCaP cells
grown in the absence and presence of 100 nM DHT. DNA fragments generally range between 150 and 900 bp. B, Digested chromatin of LNCaP cells
grown in the absence and presence of 100 nM DHT was used in the immunoprecipitation experiment with anti-AR antibody or normal mouse
immunoglobulin G. Afterward, the protein–DNA crosslink was reversed, and purified DNA was used in the PCR reactions with primers flanking the
nARE region. C, Three oligo probes were designed to cover the 2191/291 bp region in the promoter of SRD5A3. D, AR binds to the nARE of SRD5A3.
The three (biotin-labeled) oligo probes were incubated with LNCaP cell nuclear extract, with LNCaP cell nuclear extract plus unlabeled oligo probes,
or with LNCaP cell nuclear extract plus AR-specific antibody.
doi:10.1371/journal.pone.0028840.g006
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transcription of SRD5A1 and SRD5A2, which is mediated by AR
downstream transcription factors. It is also possible that AR can
directly regulate the transcription of SRD5A1 and SRD5A2 but
with AREs located in the distal promoter, enhancer, or introns of
the genes, which were not uncovered by our study.
Squelching may be another mechanistic possibility for AR-
mediated transcription repression. AR has been reported to
interact with the general transcription factor TFIIF [47], and AR
can compete with T-cell factor (TCF) for binding with b-catenin,
thus leading to the suppression of b-catenin/TCF-related
transcription [48]. For negative regulation of SRD5A3 gene
expression, we cannot rule out the possibility that AR competes
for interaction with general transcription factors, thus interfering
with the transcription of SRD5A3. However, given the direct
binding of AR to the promoter of SRD5A3 as suggested by our
ChIP and EMSA experiments, we believe that such a regulatory
mechanism is unlikely.
SRD5A3 is reportedly overexpressed in hormone-refractory
samples from patients [10,11]. These reports suggest potential
stage-dependent expression of 5a-reductase type in the prostate
from SRD5A2 to SRD5A1 and SRD5A3, which is consistent with
the fact that the use of 5a-reductase inhibitors is more relevant in
early than in more advanced prostate cancers. It remains
controversial whether SRD5A3 enzyme activity can be inhibited
by finasteride or dutasteride. Although Yamana et al. reported
that finasteride and dutasteride can block the activity of SRD5A3
[49], Titus and Mohler [11] stated in a book chapter that the 5a-
reductase inhibitor dutasteride does not inhibit the activity of
SRD5A3. The presence and expression level of SRD5A3, which is
dependent on the presence of androgens (i.e., repression of
SRD5A3 by androgens), could be an important contributor to
resistance to therapy with a 5a-reductase inhibitor. Therefore, the
role of SRD5A3 in both prostate cancer progression and
prevention is worth further investigation.
The differing expression of 5a-reductase isoenzymes may also
contribute to response or resistance to 5a-reductase inhibitors.
Because AR regulates 5a-reductase expression in a cell type–
dependent manner, we would not expect to prevent prostate
cancer in all men by administering finasteride (a specific SRD5A2
inhibitor) or dutasteride (an inhibitor of both SRD5A1 and
SRD5A2); this concurs with the results of the PCPT and
REDUCE trials. Additionally, whether the androgen regulation
of 5a-reductase isoenzymes is testosterone- or DHT-driven needs
further investigation. It also remains to be seen whether 5a-
reductases are regulated by AR in a ligand-independent manner.
This points to the fact that we may need combination therapy,
possibly inhibiting 5a-reductase isoenzymes, the AR, and other
factors involved in ligand-independent AR activation for efficient
prevention of prostate cancer in all men.
Supporting Information
Figure S1 DHT regulates the mRNA level of 5a-reduc-
tase in VCaP cells. In this experiment, VCaP cells were treated
with ethanol (vehicle only) or with 1 nM, 10 nM, or 100 nM
DHT for 24 hours. We quantified the mRNA levels of SRD5A1,
SRD5A2, and SRD5A3 by using qRT-PCR. *p,0.05, ** p,0.01,
*** p,0.001; 2-sided t test.
(TIF)
Figure S2 Testosterone regulates the mRNA level of 5a-
reductase differently in different prostate cell lines.
LNCaP (A), PWR-1E (B), BPH-1-AR (C), LAPC-4 (D), and C4-
2B4 (E) cells were treated with ethanol (vehicle only) or with 1 nM,
10 nM, or 100 nM testosterone for 24 hours. The mRNA levels of
SRD5A1, SRD5A2, and SRD5A3 for all cells were quantified by
using qRT-PCR. *p,0.05, **p,0.01, ***p,0.001; 2-sided t test.
(TIF)
Figure S3 The synthetic androgen R1881 regulates the
mRNA level of 5a-reductase differently in different
prostate cell lines. LNCaP (A), PWR-1E (B), BPH-1-AR (C),
LAPC-4 (D), and C4-2B4 (E) cells were treated with ethanol
(vehicle only) or 1 nM, 10 nM, or 100 nM R1881for 24 hours.
The mRNA levels of SRD5A1, SRD5A2, and SRD5A3 for all cells
were quantified by using qRT-PCR. *p,0.05, **p,0.01,
***p,0.001; 2-sided t test.
(TIF)
Figure S4 Regulation of 5a-reductase mRNA level by
DHT is AR dependent in LAPC-4 cells. A, The AR protein
level was analyzed by Western blotting with no siRNA, control
siRNA, and four AR siRNA treatments. AR siRNA#1 and AR
siRNA#2 had a stronger knockdown effect than the other two AR
siRNAs did. B, LAPC-4 cells were treated with no siRNA, control
siRNA or with AR siRNAs (siRNAs #1 and #2), followed by
treatment with 2 nM DHT. The mRNA level of SRD5A1 was
measured by using qRT-PCR and normalized to b-actin. The
changes in mRNA levels resulting from DHT treatment are shown
relative to the levels in cells treated with vehicle only.
(TIF)
Figure S5 Mutations in the nARE of SRD5A3 impair its
binding with the AR. Mutations were made in the sequence of
Figure 7. The SRD5A3 mRNA level is lower in androgen-
dependent xenografts than it is in androgen-independent
AR-negative SCPC xenografts. PSA (top) and SRD5A3 (bottom)
mRNA levels were analyzed by qRT-PCR for the androgen-dependent
xenograft MDA PCa 183 and the androgen-independent AR-negative
SCPC xenografts MDA PCa 144, MDA PCa 146, and MDA PCa 155.
doi:10.1371/journal.pone.0028840.g007
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incubated alone (lane 1), with LNCaP cell nuclear extract (lane 2),
with LNCaP cell nuclear extract and unlabeled oligo probe 1 (lane
3), or with LNCaP cell nuclear extract plus unlabeled mutated
oligo probe 1 (lane 4).
(TIF)
Table S1 Characteristics of the cell lines.
(DOC)
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